High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Phase 2

Recruiting

• Conditions: Breast Cancer
• Interventions: Drug: Palbociclib

• Registration Number: NCT04247633
• Lead Sponsor: Samsung Medical Center

Brief Summary

This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2-negative T1-2N0-1 EBC(Early Breast Cancer)

Detailed Description

The investigators hypothesized that the GenesWell™ BCT may help inform decision about whether or not to have adjuvant chemotherapy to patients with high-risk pN0-N1, ER+/HER2- breast cancer in Korea. While adjuvant therapy for ER-positive EBC is effective in reducing risk of recurrence and improving survival, recurrences are still common, especially in patients with unfavorable factors in terms of clinical, pathological and/or molecular perspectives.

Since the addition of CDK4/6 inhibitor, palbociclib, to endocrine therapy (ET) has proven clinical efficacy with tolerable toxicity profile in ER-positive, HER2-negative advanced BC, its use in the adjuvant setting may decrease risk of recurrences in patients with ER-positive, HER2-negative EBC after surgical resection of the primary tumor by enhancing primary endocrine responsiveness and preventing, or delaying the development of acquired resistance for endocrine therapy.

The purpose of this study is to evaluate the effect of addition of palbociclib to standard adjuvant ET on event-free survival (EFS) in patients with ER-positive, HER2-negative EBC but unfavorable clinicopathological (clinical high risk, C-high) and molecular features (genomic high risk, G-high).

Study Timeline

• Study First Submitted: 2020-01-27
• Study First Submitted QC: 2020-01-27
• Study First Posted: 2020-01-30
• Study Start: 2020-02-11
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-17
• Last Update Posted: 2020-04-20
• Primary Completion: 2023-02
• Study Completion: 2025-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 578

Inclusion Criteria

1. Patient is an adult, ≥ 19 years old at the time of informed consent
2. Premenopausal and postmenopausal women or men with invasive breast cancer
3. De novo primary disease
4. Patient who performed surgery with curative aim
5. Patient who has negative surgical resection margins
6. Patient with histologically confirmed HER2-negative breast cancer
7. Patient with histologically and cytologically confirmed ER positive breast cancer by local laboratory testing
8. Pathological node assessment: pN0 or pN1
9. Tumor size ≥ 0.5 cm, and T1 or T2
10. Clinical High-Risk (Clinical high-risk patients as per the modified Adjuvant! Online guideline in the clinical trial MINADCT(Microarray in Node Negative Disease May Avoid Chemotherapy), refer to section 5.2.1)
11. Genomic High-Risk in BCT score (≥ 4)
12. Patients agreed to use effective contraception or not be of childbearing potential.
13. Patient has adequate bone marrow and organ function
14. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
15. Patient who is able to swallow and retain oral medication
16. A FFPE tumor sample must be available for inclusion. The tumor sample must be taken from the excised primary tumor

Exclusion Criteria

1. Patient with recurred breast cancer
2. Patient with histologically confirmed ER negative
3. Patient with histologically confirmed HER2-positive
4. Pathological node assessment: pN2 or pN3
5. Patients has received neoadjuvant chemotherapy or endocrine therapy
6. Patient has received preoperative treatment with CDK 4/6 inhibitors.
7. Patient has received preoperative radiation therapy
8. Tumor size less than 0.5 cm
9. Patients with low clinical risk group (section 5.2.1)
10. Patients who low BCT risk group (BCT score<4)
11. Patients with lactose intolerance
12. Patients with a hypersensitivity to IP and/or components of IP
13. Pregnant women, women of childbearing potential or lactating women
14. Patients who have serious underlying co-morbidities which could cause end-organ dysfunction
15. A FFPE tumor sample is not available

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
palbociclib plus endocrine therapy treatement	Palbociclib	* Patients with Clinical high risk/Genomic High risk (in BCT score)-high and ER positive/HER2 negative EBC after Curative Surgery * Palbociclib at a dose of 125mg, orally once daily on Day 1 to Day 21 followed by 7 days off in a 28-day cycle for a total duration of 2 years * Standard adjuvant endocrine therapy for a duration of at least 5 years from the start of the treatment.

Primary Outcome Measures

Name	Time	Method
3-year event-free survival	up to 3 years	defined to be time from study entry to first event, where the first event is any type of recurrence

Secondary Outcome Measures

Name	Time	Method
Prognostic and predictive effects of BCT	up to 5 years	BCT score (of GenesWell™ BCT) as a biomarker to determine the efficacy of palbociclib in combination with endocrine therapy in adjuvant setting in T1-2N0-1 high risk ER+ EBC. Performance analysis of BCT score (of GenesWell™ BCT) about predicting the effectiveness of IP.; * BCT Score 0 - 4 (\<4) :Low risk (G-low); * BCT score 4 - 10 (≥4) High risk (G-high)
Exploratory analysis of genomic biomarkers	up to 5 years	Analysis of tumor/blood biomarker
overall survival	up to 5 years	defined to be time from study entry to the death from any cause. Patients who lost to follow-up or have withdrawn consent to be followed will be censored at their date of last contact or withdrawal of consent to be followed, whichever occurs first.
Adverse Events	up to 2 years	Toxicity (Adverse Events) will be collected and evaluated according to the NCI CTCAE ver. 5.0
Quality of Life (QoL)	up to 5 years	The QoL will be evaluated using European Organization for Research and Treatment of Cancer QoL Questionnaire (EORTC QLQ-C30, and B-23); -These two tools for measuring quality of life were evaluated on a scale of 100 in accordance with the formula. The higher the score, the better the quality of life, and the higher the score, the more appealing the symptom scale.

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of